Pfizer (NYSE:PFE) Price Target Cut to $35.00 by Analysts at Guggenheim

Key Points

• Guggenheim cut its price target on Pfizer from $36 to $35 but kept a buy rating, implying about 44.5% upside from the current price.
• Overall analyst sentiment remains cautious: Pfizer’s consensus rating is Hold, with a consensus price target of $28.50 based on MarketBeat data.
• Pfizer recently reported Q1 earnings above expectations, posting $0.75 EPS on $14.45 billion in revenue, and the company reaffirmed its FY2026 EPS guidance of $2.80–$3.00.

Pfizer (NYSE:PFE - Get Free Report) had its price target dropped by analysts at Guggenheim from $36.00 to $35.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. Guggenheim's price target points to a potential upside of 44.54% from the company's current price.

Several other equities analysts have also commented on PFE. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $27.00 target price on shares of Pfizer in a report on Monday, July 6th. UBS Group reissued a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Royal Bank Of Canada upgraded shares of Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price target for the company in a research report on Tuesday, June 9th. Wolfe Research reaffirmed an "underperform" rating and set a $26.00 price objective on shares of Pfizer in a research note on Thursday, May 14th. Finally, JPMorgan Chase & Co. decreased their price objective on Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and a consensus price target of $28.50.

Pfizer Stock Performance

NYSE:PFE opened at $24.21 on Monday. The company has a market capitalization of $138.01 billion, a price-to-earnings ratio of 18.48 and a beta of 0.35. The business has a 50 day moving average of $25.37 and a 200 day moving average of $26.19. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer has a 1-year low of $23.11 and a 1-year high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analysts' expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business's quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the business earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer will post 2.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Horizon Financial Services LLC grew its stake in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 645 shares during the period. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at $26,000. YANKCOM Partnership bought a new stake in shares of Pfizer during the 4th quarter valued at $28,000. HFM Investment Advisors LLC grew its position in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. grew its position in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 566 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.